TurnerTrends Stock Rating Report for BPUR
Data valid for week beginning July 14, 2008
|
BPUR [News]
|
Biopure Corp
|
Company Profile
"Biopure Corporation develops, manufactures, and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. It offers Hemopure for the treatment of adult surgical patients who are acutely anemic, as well as for eliminating, delaying, or reducing the need for red blood cell transfusions in these patients. The company also provides Oxyglobin, a veterinary product for the treatment of anemia in dogs. In addition, Biopure Corporation is developing Hemopure for a potential indication in cardiovascular ischemia and an out-of-hospital trauma indication. It has a collaboration with the U.S. Naval Medical Research Center for the development of Hemopure (HBOC-201) as a platform for the first multifunction blood substitute for trauma patients. The company markets Hemopure in South Africa, and Oxyglobin in the United States and the European Union. Biopure Corporation was founded in 1984 and is headquartered in Cambridge, Massachusetts."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Mon, 7 Jul 2008 14:56:22 Etc/GMT | Biopure plans blood substitute study (AP) | | Mon, 7 Jul 2008 11:49:00 Etc/GMT | Biopure Announces Meeting With FDA (PR Newswire) | | Thu, 3 Jul 2008 10:41:04 Etc/GMT | BIOPURE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, (EDGAR Online) | | Wed, 2 Jul 2008 20:18:00 Etc/GMT | Biopure Announces Private Equity Financing (PR Newswire) | | Tue, 1 Jul 2008 14:06:26 Etc/GMT | BIOPURE CORP Financials (EDGAR Online Financials) | | Fri, 20 Jun 2008 13:10:37 Etc/GMT | BIOPURE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; (EDGAR Online) | | Wed, 18 Jun 2008 20:46:42 Etc/GMT | BIOPURE CORP Files SEC form 10-Q/A, Quarterly Report (EDGAR Online) | | Wed, 18 Jun 2008 20:15:00 Etc/GMT | U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R) (PR Newswire) | | Mon, 16 Jun 2008 20:32:11 Etc/GMT | BIOPURE CORP Files SEC form 10-Q, Quarterly Report (EDGAR Online) | | Thu, 12 Jun 2008 20:30:00 Etc/GMT | Biopure Granted Additional 180 Day Compliance Period by NASDAQ (PR Newswire) | | Tue, 10 Jun 2008 20:35:00 Etc/GMT | Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma (PR Newswire) | | Mon, 9 Jun 2008 12:08:00 Etc/GMT | Biopure Responds to JAMA and Meta-Analysis (PR Newswire) | | Thu, 5 Jun 2008 14:24:00 Etc/GMT | Biopure Announces MHRA Meeting Update (PR Newswire) | | Wed, 21 May 2008 21:30:00 Etc/GMT | Biopure Announces 2008 Second Quarter Financial Results (PR Newswire) | | Mon, 19 May 2008 12:30:00 Etc/GMT | Biopure Wins European Patent Challenge (PR Newswire) | | Fri, 16 May 2008 20:33:08 Etc/GMT | BIOPURE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer (EDGAR Online) | | Wed, 14 May 2008 20:35:00 Etc/GMT | Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial (PR Newswire) | | Wed, 14 May 2008 12:30:00 Etc/GMT | Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin (PR Newswire) | | Thu, 8 May 2008 12:30:00 Etc/GMT | U.S. Navy Receives Funding for Further Development of Hemopure(R) (PR Newswire) | | Wed, 7 May 2008 13:49:00 Etc/GMT | Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop (PR Newswire) | News provided by Yahoo! Finance |
|
